Argentina Continuous Glucose Monitoring Market - Strategic Insights and Forecasts (2026-2031)

The Argentina Continuous Glucose Monitoring market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 15.7% from 2026 to 2031. This expansion is expected to drive the market value from USD 28.0 million in 2026 to USD 58.0 million by 2031, primarily due to the rising prevalence of Type 1 and Type 2 diabetes.

Sensors currently hold the largest market share by component within the Argentinian CGM market. This dominance is attributed to their frequent 10–14 day replacement cycle, which consistently generates high-volume revenue for manufacturers and providers.

Self-monitoring at home is the dominant care setting for CGM adoption in Argentina, accounting for more than half of the regional market share. This prominence is driven by patients seeking convenient, patient-centric management solutions, though clinical adoption in hospitals is also expanding to complement the home-care segment.

The market is primarily driven by increasing diabetes awareness through national advocacy efforts, technological breakthroughs enabling sensor miniaturization for enhanced comfort, and a strong push for preventive healthcare. Additionally, widespread smartphone compatibility facilitates seamless integration of CGM data into daily life, bolstering device utility.

The National Administration of Drugs, Food and Medical Technology (ANMAT) is intensifying post-market surveillance to ensure safety and efficacy, while new deadlines and notification criteria increase the administrative burden for international importers. Further regulatory influence stems from the 2026 "Alliance for Primary Health Care" initiative, focused on reducing service fragmentation and closing access gaps in chronic care.

High out-of-pocket costs and limited reimbursement continue to constrain overall market penetration in price-sensitive segments, coupled with increasing regulatory complexity from new ANMAT criteria. However, strategic global partnerships, such as the Abbott and Medtronic integration, and the expansion of mobile health platforms through telehealth integration represent significant opportunities to simplify management and enhance device utility.